The Health Resources andServices Administration (HRSA) has sent a letter to Boehringer Ingelheim ordering the pharmaceutical company to comply with federal requirements under the 340B drug pricing program.
HRSA orders Boehringer Ingelheim to comply with 340B drug pricing
